title: [Relationship between serum galectin-3 levels and mortality of subacute on chronic liver failure].
abstract: OBJECTIVE
  To study the correlation between clinically detected serum galectin-3 levels and prognosis of liver failure.
  
  
  METHODS
  Fifty-five patients diagnosed with liver failure were administered a combined modality therapy and followed up until death or for 6 months. Fifty-five patients with liver failure were administered a combined modality therapy and followed up until death or for 6 months. In addition, 30 patients with chronic hepatitis B (CHB) and 30 healthy volunteers were matched for use as controls. Serum galectin-3 levels were detected at baseline and last follow-up visit and compared between groups by statistical analysis.
  
  
  RESULTS
  At baseline, the CHB group had a significantly higher level of serum galectin-3 than the healthy control group (F=2.701, P less than 0.01). However, the galectin-3 level 5 of the liver failure group was significantly higher than that of both the CHB group (F=8.121, P less than 0.01) and the healthy control group (F=11.231, P less than 0.01). When patients within the liver failure group were divided by survival and death occurring during the 6-month follow-up period, the patients who died (n=28) were found to have a significantly higher level of serum galectin-3 than the surviving patients (n=27) (P less than 0.01). The area under the curve of ROC curve is 0.766, and cut off value is 0.246 5 ng/ml.
  
  
  CONCLUSIONS
  The level of serum galectin-3 is positively correlated with risk of death in patients with liver failure. Up-regulation of galectin-3 may act as a protective factor in patients with severe liver injury.
authors.affiliation: Department of Heavy Medicine, the Second Hospital of Nanjing, Affiliated to Southeast University, Nangjing 210003 China.
authors.forename: Yishan
authors.initials: Y
authors.lastname: Zheng
authors.forename: Zongsheng
authors.initials: Z
authors.lastname: Wu
authors.forename: Lei
authors.initials: L
authors.lastname: Dong
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Lingyan
authors.initials: L
authors.lastname: Xiao
authors.forename: Dong-Yang
authors.initials: DY
authors.lastname: Shi
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D001798:Blood Proteins; D016022:Case-Control Studies; D005260:Female; D037502:Galectin 3 / Q000097:blood*; D037161:Galectins; D019694:Hepatitis B, Chronic / Q000097:blood; D006801:Humans; D017093:Liver Failure / Q000097:blood* / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D001798:Blood Proteins; D037502:Galectin 3; D037161:Galectins; C428445:LGALS3 protein, human